Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity - USD ($) $ in Thousands	Total	IPO	Share Purchase Agreement	Common Stock	Common Stock IPO	Common Stock Share Purchase Agreement	Additional Paid-in Capital	Additional Paid-in Capital IPO	Additional Paid-in Capital Share Purchase Agreement	Accumulated Other Comprehensive Loss	Accumulated Deficit	Series A-1, A-2 and B Convertible Preferred Stock	Series A-1, A-2 and B Convertible Preferred Stock Preferred Stock
Beginning balance at Dec. 31, 2019													$ 86,544
Beginning balance (in shares) at Dec. 31, 2019													28,615,546
Increase (Decrease) in Temporary Equity
Issuance of Series B convertible preferred stock, net of issuance costs												$ 89,861
Issuance of Series B convertible preferred stock, net of issuance costs (in shares)													12,007,867
Conversion of preferred stock to common stock												$ (176,405)
Conversion of preferred stock to common stock (in shares)													(40,623,413)
Ending balance at Dec. 31, 2020													$ 0
Ending balance (in shares) at Dec. 31, 2020													0
Beginning balance at Dec. 31, 2019	$ (88,016)			$ 0			$ 6,120				$ (94,136)
Beginning balance (in shares) at Dec. 31, 2019				4,870,851
Increase (Decrease) in Stockholders' Equity
Conversion of preferred stock to common stock	176,405			$ 3			176,402
Conversion of preferred stock to common stock (in shares)				21,958,588
Issuance of stock during the period new shares issued		$ 122,121			$ 1			$ 122,120
Stock issued during the period shares new issues shares (in shares)					8,451,837
Conversion of warrant liability to equity upon closing of initial public offering	114						114
Issuance of common stock in connection with the cashless exercise of warrants				6,728
Issuance of common stock upon exercise of stock options	1,221						1,221
Issuance of common stock upon exercise of stock options (in shares)				611,048
Issuance of warrants in connection with notes payable	188						188
Vesting of restricted stock (in shares)				891,894
Stock-based compensation expense	2,961						2,961
Unrealized losses on marketable securities	(7)									$ (7)
Net loss	(68,800)										(68,800)
Ending balance at Dec. 31, 2020	$ 146,187			$ 4			309,126			(7)	(162,936)
Ending balance (in shares) at Dec. 31, 2020	36,790,946			36,790,946
Ending balance at Dec. 31, 2021													$ 0
Ending balance (in shares) at Dec. 31, 2021													0
Increase (Decrease) in Stockholders' Equity
Issuance of stock during the period new shares issued			$ 42,205						$ 42,205
Stock issued during the period shares new issues shares (in shares)						4,000,000
Issuance of common stock upon exercise of stock options	$ 1,418						1,418
Issuance of common stock upon exercise of stock options (in shares)	508,774			508,774
Stock-based compensation expense	$ 8,384						8,384
Unrealized losses on marketable securities	(3)									(3)
Net loss	(101,320)										(101,320)
Ending balance at Dec. 31, 2021	$ 96,871			$ 4			$ 361,133			$ (10)	$ (264,256)
Ending balance (in shares) at Dec. 31, 2021	41,299,720			41,299,720